Nanosonics Limited (ASX:NAN)
Australia · Delayed Price · Currency is AUD | Market Cap | 1.04B -28.3% |
| Revenue (ttm) | 207.26M +12.7% |
| Net Income | 20.56M +24.1% |
| EPS | 0.07 +24.7% |
| Shares Out | 299.23M |
| PE Ratio | 52.18 |
| Forward PE | 54.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 161,546 |
| Average Volume | 407,245 |
| Open | 3.490 |
| Previous Close | 3.470 |
| Day's Range | 3.310 - 3.490 |
| 52-Week Range | 3.210 - 4.870 |
| Beta | 1.21 |
| RSI | 44.24 |
| Earnings Date | Feb 23, 2026 |
About Nanosonics
Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabi... [Read more]
Financial Performance
In fiscal year 2025, Nanosonics's revenue was 198.63 million, an increase of 16.83% compared to the previous year's 170.01 million. Earnings were 20.68 million, an increase of 59.39%.
Financial StatementsNews
Nanosonics Earnings Call Transcript: H1 2026
Revenue grew 9% year-over-year to AUD 102 million, with strong recurring revenue and operating margin expansion. Guidance for 8%-12% revenue growth is reaffirmed, supported by upgrades, new product launches, and disciplined cost management.
Nanosonics upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital upgraded Nanosonics (NNCSF) to Sector Perform from Underperform with an unchanged price target of A$4. The firm views the shares as fairly valued now that earnings estimates have…
Nanosonics Transcript: AGM 2025
The meeting highlighted strong financial growth, new product launches, and a disciplined capital management approach, including a share buyback. Strategic focus remains on innovation, international expansion, and sustainability, with all resolutions passed and active engagement with shareholders throughout.
Nanosonics downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital downgraded Nanosonics (NNCSF) to Underperform from Sector Perform with a price target of A$4, down from A$4.50. The company’s fiscal 2026 outlook fell significantly below estimates due to…
Nanosonics Earnings Call Transcript: H2 2025
Revenue grew 17% to AUD 198.6 million, with recurring revenue up 20% and profit before tax up 72%. FY 2026 guidance anticipates 8–12% revenue growth, gross margin of 75–77%, and continued investment in innovation, with minimal CORIS revenue expected.
Nanosonics upgraded to Buy from Hold at Canaccord
Canaccord analyst Elyse Shapiro upgraded Nanosonics (NNCSF) to Buy from Hold with a price target of A$4.74, up from A$4.47. FDA De Novo approval for the company’s Coris device for…
Nanosonics Earnings Call Transcript: H1 2025
Revenue rose 18% year-over-year to AUD 93.6 million, with strong growth in North America and Europe. Full-year revenue guidance was raised to 11%-14%, gross margin improved to 78.5%, and net profit increased 58%. Cash balance stands at AUD 144.5 million, with no debt.
Nanosonics Transcript: AGM 2024
The meeting reviewed a return to growth in FY 2024, with strong H2 performance, robust margins, and ongoing investment in R&D and sustainability. Strategic focus remains on expanding the trophon base, launching CORIS pending FDA approval, and strengthening governance and diversity. Shareholders discussed regulatory, competitive, and operational risks.
Nanosonics Earnings Call Transcript: H2 2024
Second half FY24 saw a strong revenue rebound, driven by capital unit sales and recurring revenue growth. FY25 guidance targets 8%-12% revenue growth, margin recovery, and continued investment in R&D and M&A, with hospital budget constraints easing but still present.
Nanosonics Earnings Call Transcript: H1 2024
Nanosonics Transcript: AGM 2023
Nanosonics initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Nanosonics with a Sector Perform rating and A$5.25 price target. Nanosonics trophon device offers a unique automated solution for high level disinfection of ultrasoun...